Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBP-2011
- Development stage
- Preclinical
- Lead developer
- Oncolys BioPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OBP-2011 is an orally available small molecule compound developed to specifically inhibit the replication of the novel coronavirus SARS-CoV-2, which causes COVID-19. The drug has demonstrated efficacy in preclinical studies against SARS-CoV-2 and has also shown effects against other coronaviruses such as SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome). OBP-2011 is being developed by Oncolys BioPharma in collaboration with Kagoshima University, with a focus on providing an antiviral therapy that can be administered orally to suppress viral replication. As of now, it remains in preclinical development[1][3].
Beyond the preview
Go deeper on OBP-2011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBP-2011.